$PCRX
Pacira Biosciences Inc Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-Q Financial Statement

#000110465912073140 Filed on November 01, 2012

Income Statement

Concept	2012 Q4	2012 Q3	2011 Q3
Revenue	$10.45M	$8.486M	$3.956M
YoY Change	148.81%	114.51%	-12.71%
Cost Of Revenue	$9.672M	$9.287M	$3.357M
YoY Change	46.55%	176.65%	-6.05%
Gross Profit	$778.0K	-$801.0K	$599.0K
YoY Change	-132.42%	-233.72%	-37.54%
Gross Profit Margin	7.44%	-9.44%	15.14%
Selling, General & Admin	$13.40M	$11.38M	$4.972M
YoY Change	86.11%	128.84%	193.51%
% of Gross Profit	1722.37%		830.05%
Research & Development	$3.200M	$3.527M	$4.360M
YoY Change	52.38%	-19.11%	-23.72%
% of Gross Profit	411.31%		727.88%
Depreciation & Amortization	$1.450M	$900.0K	$400.0K
YoY Change	13.28%	125.0%	-60.78%
% of Gross Profit	186.38%		66.78%
Operating Expenses	$26.28M	$24.19M	$12.69M
YoY Change	179.56%	90.65%	15.53%
Operating Profit	-$25.50M	-$15.71M	-$8.733M
YoY Change	116.11%	79.85%	-12.88%
Interest Expense	-$300.0K	$456.0K	$910.0K
YoY Change	-50.0%	-49.89%	-15.51%
% of Operating Profit
Other Income/Expense, Net	-$200.0K	-$39.00K	-$775.0K
YoY Change		-94.97%	-46.51%
Pretax Income	-$16.30M	-$15.75M	-$9.500M
YoY Change	6.54%	65.74%	20.25%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$16.35M	-$15.75M	-$9.508M
YoY Change	6.84%	65.6%	20.35%
Net Earnings / Revenue	-156.42%	-185.54%	-240.34%
Basic Earnings Per Share		-$0.49	-$0.55
Diluted Earnings Per Share	-$500.0K	-$0.49	-$0.55
COMMON SHARES
Basic Shares Outstanding	32.55M shares	32.44M shares	17.23M shares
Diluted Shares Outstanding		32.44M shares	17.23M shares

Balance Sheet

Concept	2012 Q4	2012 Q3	2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$41.10M	$66.90M	$37.10M
YoY Change	-46.06%	80.32%	166.91%
Cash & Equivalents	$12.52M	$8.709M	$16.40M
Short-Term Investments	$30.90M	$58.20M	$20.70M
Other Short-Term Assets	$3.400M	$3.800M	$3.200M
YoY Change	9.68%	18.75%	6.67%
Inventory	$12.08M	$11.91M	$1.700M
Prepaid Expenses
Receivables	$4.352M	$2.459M	$1.500M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$60.92M	$85.13M	$43.40M
YoY Change	-26.29%	96.15%	112.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$39.12M	$35.32M	$25.80M
YoY Change	55.82%	36.9%	18.35%
Goodwill	$8.297M	$8.109M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$511.0K	$548.0K	$1.200M
YoY Change	6.68%	-54.33%	9.09%
Total Long-Term Assets	$51.13M	$47.70M	$34.21M
YoY Change	65.79%	39.43%	5.58%
TOTAL ASSETS
Total Short-Term Assets	$60.92M	$85.13M	$43.40M
Total Long-Term Assets	$51.13M	$47.70M	$34.21M
Total Assets	$112.1M	$132.8M	$77.61M
YoY Change	-1.27%	71.15%	46.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.569M	$4.789M	$4.300M
YoY Change	-25.32%	11.37%	-38.57%
Accrued Expenses	$9.792M	$13.04M	$5.000M
YoY Change	36.78%	160.72%	66.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$800.0K	$6.200M
YoY Change	-100.0%	-87.1%	287.5%
Total Short-Term Liabilities	$14.16M	$19.83M	$17.83M
YoY Change	-55.64%	11.21%	29.2%
LONG-TERM LIABILITIES
Long-Term Debt	$25.19M	$24.93M	$22.40M
YoY Change	35.9%	11.29%	-58.44%
Other Long-Term Liabilities	$2.275M	$2.399M	$23.50M
YoY Change	-18.11%	-89.79%	-16.37%
Total Long-Term Liabilities	$27.47M	$27.33M	$45.90M
YoY Change	28.86%	-40.46%	-44.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.16M	$19.83M	$17.83M
Total Long-Term Liabilities	$27.47M	$27.33M	$45.90M
Total Liabilities	$46.20M	$52.38M	$63.73M
YoY Change	-29.17%	-17.81%	-33.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$232.5M	-$216.2M
YoY Change	29.01%
Common Stock	$33.00K	$32.00K
YoY Change	32.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.000K	$2.000K
YoY Change	0.0%
Treasury Stock Shares	1.065K shares	1.065K shares	1.065K shares
Shareholders Equity	$65.86M	$80.45M	$13.90M
YoY Change
Total Liabilities & Shareholders Equity	$112.1M	$132.8M	$77.60M
YoY Change	-1.27%	71.17%	46.97%

Cashflow Statement

Concept	2012 Q4	2012 Q3	2011 Q3
OPERATING ACTIVITIES
Net Income	-$16.35M	-$15.75M	-$9.508M
YoY Change	6.84%	65.6%	20.35%
Depreciation, Depletion And Amortization	$1.450M	$900.0K	$400.0K
YoY Change	13.28%	125.0%	-60.78%
Cash From Operating Activities	-$21.18M	-$11.18M	-$8.490M
YoY Change	178.68%	31.68%	22.87%
INVESTING ACTIVITIES
Capital Expenditures	-$4.730M	-$6.260M	-$1.640M
YoY Change	89.96%	281.71%	-13.68%
Acquisitions
YoY Change
Other Investing Activities	$27.09M	$4.450M	-$910.0K
YoY Change	-391.6%	-589.01%
Cash From Investing Activities	$22.36M	-$1.810M	-$2.570M
YoY Change	-290.14%	-29.57%	35.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	240.0K	250.0K	10.00K
YoY Change	-99.51%	2400.0%	-99.9%
NET CHANGE
Cash From Operating Activities	-21.18M	-11.18M	-8.490M
Cash From Investing Activities	22.36M	-1.810M	-2.570M
Cash From Financing Activities	240.0K	250.0K	10.00K
Net Change In Cash	1.420M	-12.74M	-11.05M
YoY Change	-95.23%	15.29%	-836.67%
FREE CASH FLOW
Cash From Operating Activities	-$21.18M	-$11.18M	-$8.490M
Capital Expenditures	-$4.730M	-$6.260M	-$1.640M
Free Cash Flow	-$16.45M	-$4.920M	-$6.850M
YoY Change	221.92%	-28.18%	36.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	25000	USD
CY2011Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	29970000	USD
CY2011Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	10000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8709000	USD
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1299000	USD
CY2011Q4	us-gaap	Short Term Investments ShortTermInvestments	29985000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2113000	USD
CY2011Q4	us-gaap	Inventory Net InventoryNet	1245000	USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1839000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	82649000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25103000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	479000	USD
CY2011Q4	us-gaap	Assets Assets	113490000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3440000	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7159000	USD
CY2011Q4	pcrx	Royalty Interest Obligation Current RoyaltyInterestObligationCurrent	1219000	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13054000	USD
CY2011Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	7039000	USD
CY2011Q4	pcrx	Royalty Interest Obligation Noncurrent RoyaltyInterestObligationNoncurrent	1537000	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8416000	USD
CY2011Q4	pcrx	Contingent Purchase Liability ContingentPurchaseLiability	2042000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2778000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	65221000	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	25000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	228470000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-180239000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	15000	USD
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	48269000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113490000	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	80445000	USD
CY2012Q3	us-gaap	Liabilities Liabilities	52381000	USD
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	19828000	USD
CY2012Q3	us-gaap	Assets Assets	132826000	USD
CY2012Q3	us-gaap	Assets Current AssetsCurrent	85129000	USD
CY2012Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32483878	shares
CY2012Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32482813	shares
CY2012Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1791000	USD
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25340103	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25339038	shares
CY2012Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	1065	shares
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1065	shares
CY2011Q3	pcrx	Supply And Royalty Revenue SupplyAndRoyaltyRevenue	1682000	USD
CY2011Q3	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	1352000	USD
	pcrx	Supply And Royalty Revenue SupplyAndRoyaltyRevenue	4868000	USD
	us-gaap	Revenues Revenues	11456000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12742000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12960000	USD
	us-gaap	Operating Expenses OperatingExpenses	35840000	USD
	us-gaap	Depreciation Depreciation	2700000	USD
CY2011Q3	us-gaap	Depreciation Depreciation	500000	USD
	us-gaap	Depreciation Depreciation	1300000	USD
CY2012Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	58176000	USD
CY2012Q3	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	66000	USD
CY2012Q3	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	2000	USD
CY2011Q3	us-gaap	Cost Of Revenue CostOfRevenue	3357000	USD
CY2011Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4360000	USD
CY2011Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4972000	USD
CY2011Q3	us-gaap	Operating Expenses OperatingExpenses	12689000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	10138000	USD
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8733000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24384000	USD
CY2011Q3	us-gaap	Interest Expense InterestExpense	910000	USD
CY2011Q3	us-gaap	Royalty Expense RoyaltyExpense	-116000	USD
CY2011Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-27000	USD
CY2011Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-775000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	111000	USD
	us-gaap	Interest Expense InterestExpense	4068000	USD
	us-gaap	Royalty Expense RoyaltyExpense	-235000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	61000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3661000	USD
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	-9508000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28045000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.89
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-15745000	USD
CY2012Q3	us-gaap	Revenues Revenues	8486000	USD
	us-gaap	Revenues Revenues	28634000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	24192000	USD
	us-gaap	Operating Expenses OperatingExpenses	62103000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15706000	USD
CY2012Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-39000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2466000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35935000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Note 1—DESCRIPTION OF BUSINESS</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 27.5pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Pacira Pharmaceuticals, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) is an emerging specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products, based on its proprietary DepoFoam extended release drug delivery technology, for use in hospitals and ambulatory surgery centers. The Company’s lead product EXPAREL®, which consists of bupivacaine encapsulated in DepoFoam, was approved by the United States Food and Drug Administration, or FDA, on October 28, 2011. The Company commercially launched EXPAREL in April 2012. DepoFoam is also the basis for the Company’s other FDA-approved commercial product, DepoCyt(e), which the Company manufactures for its commercial partners.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 27.5pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 27.5pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Pacira Pharmaceuticals, Inc. is the holding company for the California operating subsidiary of the same name, also referred to as PPI-California, which was acquired from Skyepharma Holding, Inc., or Skyepharma, in March 2007, referred to herein as the Acquisition.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table>
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9513000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28050000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15779000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-34000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-34000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	49000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35886000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	49000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-23404000	USD
	us-gaap	Interest Paid InterestPaid	3573000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	907000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	51222000	USD
	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	16574000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	6000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-9731000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26133000	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16402000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-48951000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-37459000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	533000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3220000	USD
	dei	Entity Registrant Name EntityRegistrantName	Pacira Pharmaceuticals, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001396814
	dei	Document Period End Date DocumentPeriodEndDate	2012-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2012Q3	us-gaap	Short Term Investments ShortTermInvestments	58240000	USD
CY2012Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32553672	shares
CY2011Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17230826	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14826054	shares
CY2012Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4486000	USD
CY2012Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1032000	USD
CY2012Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6388000	USD
CY2012Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2459000	USD
CY2011Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	862000	USD
CY2011Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	96000	USD
CY2011Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	287000	USD
CY2012Q3	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	500000	USD
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	1400000	USD
CY2012Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46365000	USD
CY2012Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11046000	USD
CY2012Q3	us-gaap	Inventory Net InventoryNet	11906000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33385000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700000	USD
CY2012Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2012Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	322000	USD
CY2012Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	753000	USD
CY2012Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2050000	USD
CY2012Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	514000	USD
CY2012Q3	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	3484000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1965000	USD
CY2011Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000	USD
CY2012Q3	us-gaap	Depreciation Depreciation	900000	USD
CY2012Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2024000	USD
CY2012Q3	pcrx	Long Term Debt Including Royalty Interest Obligation LongTermDebtIncludingRoyaltyInterestObligation	26648000	USD
CY2011Q4	pcrx	Long Term Debt Including Royalty Interest Obligation LongTermDebtIncludingRoyaltyInterestObligation	28332000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3220000	USD
CY2011Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	442000	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35319000	USD
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	816054	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4388483	shares
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5204537	shares
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1469000	USD
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32436000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32436000	shares
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2011Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17231000	shares
CY2011Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17231000	shares
CY2011Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2011Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29586000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29586000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14826000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14826000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.89
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.89
	pcrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	15695000	shares
CY2011Q3	pcrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	18510000	shares
	pcrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	30991000	shares
CY2012Q3	pcrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	34037000	shares
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8282000	USD
CY2011Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	456000	USD
CY2012Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	62900000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5259000	USD
CY2012Q3	us-gaap	Goodwill Goodwill	8109000	USD
CY2012Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	548000	USD
CY2012Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4789000	USD
CY2012Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13036000	USD
CY2012Q3	pcrx	Royalty Interest Obligation Current RoyaltyInterestObligationCurrent	837000	USD
CY2012Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1166000	USD
CY2012Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	24930000	USD
CY2012Q3	pcrx	Royalty Interest Obligation Noncurrent RoyaltyInterestObligationNoncurrent	881000	USD
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	32000	USD
CY2012Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	296525000	USD
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216174000	USD
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	64000	USD
CY2012Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2000	USD
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	132826000	USD
CY2012Q3	pcrx	Supply And Royalty Revenue SupplyAndRoyaltyRevenue	4550000	USD
	pcrx	Supply And Royalty Revenue SupplyAndRoyaltyRevenue	9978000	USD
CY2012Q3	us-gaap	Royalty Revenue RoyaltyRevenue	452000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6693000	USD
CY2012Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11378000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32943000	USD
CY2012Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	87000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	218000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-15961000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-204000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13525000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3684000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	-28206000	USD
CY2011Q3	us-gaap	Royalty Revenue RoyaltyRevenue	922000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	2082000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	2743000	USD
CY2012Q3	us-gaap	Cost Of Revenue CostOfRevenue	9287000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	22467000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3527000	USD
	us-gaap	Interest Expense InterestExpense	1464000	USD
CY2012Q3	us-gaap	Royalty Expense RoyaltyExpense	-378000	USD
	us-gaap	Royalty Expense RoyaltyExpense	47000	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-48000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-111000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.21
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32436207	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29585716	shares
CY2012Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4343000	USD
CY2012Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2399000	USD
	pcrx	Stock Issued During Period Value Follow On Public Offering Issues StockIssuedDuringPeriodValueFollowOnPublicOfferingIssues	62855000	USD
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1354000	USD
CY2011Q3	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	200000	USD
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	500000	USD
	pcrx	Beginning Period Prior To Product Expiration Allowed For Returning Product BeginningPeriodPriorToProductExpirationAllowedForReturningProduct	P6M
CY2012Q2	pcrx	Payment Obligation Arising Due To First Commercial Sale Of Product In Connection With Acquisition PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition	10000000	USD
CY2012Q2	pcrx	Contingent Payment Obligation Established For Sale Of Product In Connection With Acquisition ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition	2000000	USD
CY2012Q2	us-gaap	Goodwill Goodwill	8000000	USD
	pcrx	Period After Product Expiration Upto Which Product Is Allowed To Be Returned PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned	P12M
CY2012Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	82000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4202000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3030000	USD
	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	-178000	USD
	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	-29000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	571000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1540000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1062000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3220000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1965000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	492000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	373000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	346000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	305000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10661000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	62000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	161000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	908000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6849000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	697000	USD
	pcrx	Increase Decrease In Royalty Interest Obligation IncreaseDecreaseInRoyaltyInterestObligation	1038000	USD
	pcrx	Increase Decrease In Royalty Interest Obligation IncreaseDecreaseInRoyaltyInterestObligation	1435000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-83000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	722000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	-20671000	USD
	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	10151000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-51881000	USD
CY2012Q3	pcrx	Inventory Valuation Reserve Of Product InventoryValuationReserveOfProduct	300000	USD
CY2011Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value BusinessAcquisitionContingentConsiderationAtFairValue	2000000	USD
CY2011Q4	us-gaap	Long Term Debt LongTermDebt	19211000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-24355000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	27500000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	62855000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	38016000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	26250000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	63373000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	38028000	USD
	pcrx	Debt Conversion Converted Instrument Amount Two DebtConversionConvertedInstrumentAmountTwo	1354000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1365000	USD
CY2011Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	674000	USD
CY2012Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6900000	shares
CY2012Q2	us-gaap	Share Price SharePrice	9.75
	pcrx	Number Of Major Customers NumberOfMajorCustomers	4	item
CY2011	pcrx	Number Of Major Customers NumberOfMajorCustomers	2	item
CY2011Q4	pcrx	Royalty Interest Obligation RoyaltyInterestObligation	2756000	USD
CY2012Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2570000	USD
CY2012Q3	us-gaap	Long Term Debt LongTermDebt	27500000	USD
CY2012Q3	pcrx	Royalty Interest Obligation RoyaltyInterestObligation	1718000	USD
CY2012Q3	pcrx	Goodwill Recorded For Earn Out Payments GoodwillRecordedForEarnOutPayments	200000	USD
CY2012Q3	pcrx	Debt Instrument Carrying Amount Net Of Discount DebtInstrumentCarryingAmountNetOfDiscount	24930000	USD
CY2011Q4	pcrx	Debt Instrument Carrying Amount Net Of Discount DebtInstrumentCarryingAmountNetOfDiscount	25576000	USD
CY2012Q2	pcrx	Management Agreement Contract Sum ManagementAgreementContractSum	7700000	USD
CY2011Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	18537000	USD
	pcrx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	100000	USD
	pcrx	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	633000	USD
	pcrx	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	12000	USD
CY2011Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5000	USD
CY2011Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-5000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-5000	USD
	us-gaap	Interest Paid InterestPaid	3290000	USD
CY2012Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	400000	USD
CY2011Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD

Files In Submission

Name	View Source	Status
0001104659-12-073140-index-headers.html	Edgar Link	pending
0001104659-12-073140-index.html	Edgar Link	pending
0001104659-12-073140.txt	Edgar Link	pending
0001104659-12-073140-xbrl.zip	Edgar Link	pending
a12-20102_110q.htm	Edgar Link	pending
a12-20102_1ex10d1.htm	Edgar Link	pending
a12-20102_1ex31d1.htm	Edgar Link	pending
a12-20102_1ex31d2.htm	Edgar Link	pending
a12-20102_1ex32d1.htm	Edgar Link	pending
a12-20102_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g201021kei001.jpg	Edgar Link	pending
pcrx-20120930.xml	Edgar Link	completed
pcrx-20120930.xsd	Edgar Link	pending
pcrx-20120930_cal.xml	Edgar Link	unprocessable
pcrx-20120930_def.xml	Edgar Link	unprocessable
pcrx-20120930_lab.xml	Edgar Link	unprocessable
pcrx-20120930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira Biosciences Inc Stock $pcrx

2012 Q4 Form 10-Q Financial Statement

#000110465912073140 Filed on November 01, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira Biosciences Inc Stock $pcrx

2012 Q4 Form 10-Q Financial Statement

#000110465912073140 Filed on November 01, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira Biosciences Inc Stock $pcrx